Clinical Trial Update: Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy [Phase 2]

View source ↗

Summary

This report covers a Phase 2 trial evaluating eribulin in patients who did not achieve pathologic complete response after neoadjuvant chemotherapy for breast ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Halaven (eribulin)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-05-07